FULCRUM THERAPEUTICS INC (FULC)

What FULCRUM THERAPEUTICS INC does

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing genetically-defined rare disease treatments. The company focuses on discovering and developing product candidates through research and preclinical studies, with pociredir as its lead clinical program. Fulcrum operates in early development stages and has not yet completed development of any product candidates or achieved regulatory approval, relying on collaboration agreements and equity financing to fund operations.

Fundamentals

• Price$3.59 as of 2026-07-09 close
• Market cap$240M as of 2026-07-10
• 1-year return-52.5% as of 2026-07-09 close
• Net margin+8.1% as of 2026-07-10
• ROE-22.5% as of 2026-07-10
• Debt / equity0.00 as of 2026-07-10
• Beta2.59 as of 2026-07-10

Ask why FULC looks like this →

Key risks (from latest filing)

["Significant accumulated losses ($594.3M deficit as of Dec 2025) with expectation of continued losses over several years; uncertain path to profitability despite currently being profitable on net margin basis","Pociredir development has faced regulatory holds (IND application hold on SCD indication lifted in Aug 2023) and enrollment challenges, with potential for further delays in clinical development or FDA-required additional studies","Substantial capital requirements for continued clinical development, manufacturing scale-up, regulatory approval pursuit, and commercialization infrastructure with dependence on future equity financing and collaboration milestone payments"]

See FULC's biggest risks from its latest 10-Q →

Competitors & peers

• Vertex Pharmaceuticals (VERX)
• Reata Pharmaceuticals
• Sangamo Therapeutics
• Agios Pharmaceuticals
• Ultragenyx Pharmaceutical

Not quite? Describe exactly what you want →